USD
$0.00
(0.00%
)At Close (As of Oct 23, 2025)
$5.93B
Market Cap
-
P/E Ratio
-1.78
EPS
$47.79
52 Week High
$27.34
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $393M |
| Total Revenue | $627M |
| Cost Of Revenue | $235M |
| Costof Goods And Services Sold | $235M |
| Operating Income | -$303M |
| Selling General And Administrative | $137M |
| Research And Development | $414M |
| Operating Expenses | $696M |
| Investment Income Net | - |
| Net Interest Income | $40M |
| Interest Income | $61M |
| Interest Expense | $22M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $23M |
| Income Before Tax | -$158M |
| Income Tax Expense | $19M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$177M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$137M |
| Ebitda | -$113M |
| Net Income | -$177M |
| Field | Value (USD) |
|---|---|
| Total Assets | $1.7B |
| Total Current Assets | $1.3B |
| Cash And Cash Equivalents At Carrying Value | $287M |
| Cash And Short Term Investments | $287M |
| Inventory | $24M |
| Current Net Receivables | $125M |
| Total Non Current Assets | $386M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $174M |
| Intangible Assets Excluding Goodwill | $174M |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $4.4M |
| Short Term Investments | $836M |
| Other Current Assets | $12M |
| Other Non Current Assets | - |
| Total Liabilities | $630M |
| Total Current Liabilities | $278M |
| Current Accounts Payable | $37M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $9.6M |
| Total Non Current Liabilities | $352M |
| Capital Lease Obligations | $49M |
| Long Term Debt | $301M |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $351M |
| Other Current Liabilities | $160M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $1B |
| Treasury Stock | - |
| Retained Earnings | -$1.7B |
| Common Stock | $37K |
| Common Stock Shares Outstanding | $91M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$144M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $23M |
| Capital Expenditures | $14M |
| Change In Receivables | - |
| Change In Inventory | -$17M |
| Profit Loss | - |
| Cashflow From Investment | -$851M |
| Cashflow From Financing | $5.7M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$158M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $393M |
| Total Revenue | $627M |
| Cost Of Revenue | $235M |
| Costof Goods And Services Sold | $235M |
| Operating Income | -$303M |
| Selling General And Administrative | $137M |
| Research And Development | $414M |
| Operating Expenses | $696M |
| Investment Income Net | - |
| Net Interest Income | $40M |
| Interest Income | $61M |
| Interest Expense | $22M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $23M |
| Income Before Tax | -$158M |
| Income Tax Expense | $19M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$177M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$137M |
| Ebitda | -$113M |
| Net Income | -$177M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Legend Biotech Corporation is a clinical-stage biopharmaceutical company dedicated to pioneering innovative cell therapies, particularly in oncology, through its proprietary CAR-T cell therapy platform. With a robust pipeline and a commitment to rigorous clinical research, the company is well-positioned to address substantial unmet medical needs and enhance patient outcomes. Strategic collaborations further strengthen its capabilities, making Legend Biotech a compelling prospect for institutional investors seeking exposure to advancements in immuno-oncology and transformative therapeutic solutions. As it moves forward with pivotal clinical trials, the potential for significant returns in the biopharmaceutical sector remains high.